<DOC>
	<DOCNO>NCT00003421</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know chemotherapy regimen effective advance Hodgkin 's disease . PURPOSE : Randomized phase III trial compare different combination chemotherapy regimens treat patient advance Hodgkin 's disease .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether four-drug anthracycline-based regimen seven-drug hybrid eight-drug alternate regimen optimal treatment patient advance Hodgkin 's disease . OUTLINE : This randomize study . Patients randomize one two treatment arm . Arm I ( ABVD ) : Patients receive doxorubicin IV , bleomycin IV , vinblastine IV , dacarbazine IV day 1 15 . Courses repeat every 4 week . Arm II ( ChlVPP/PABLOE ) : Patients receive oral chlorambucil , procarbazine , prednisolone day 1-14 ; vinblastine IV day 1 8 ; doxorubicin IV day 29 ; vincristine IV bleomycin IV day 29 36 ; oral etoposide day 29-31 ; oral prednisolone day 29-38 . Courses repeat every 7 week . OR ( Hybrid - ChlVPP/EVA ) : Patients receive vincristine IV day 1 ; oral etoposide day 1-5 ; oral chlorambucil , procarbazine , prednisolone day 1-7 ; doxorubicin IV vinblastine IV day 8 . Courses repeat every 4 week . Patients arm receive 6-8 course treatment . Radiotherapy may give site previous bulk disease patient complete remission uncertain remission . Patients achieve partial remission may receive radiotherapy residual disease site . Patients fail respond , disease progression , may receive induction therapy follow high-dose consolidation therapy . Patients follow every 3 month 2 year , every 6 month 5 year , annually 5 year . PROJECTED ACCRUAL : Approximately 800 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced Hodgkin 's disease require systemic therapy Stage IA IIA disease bulky disease three site involvement also eligible PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No active malignancy within 5 year HIV negative Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Hodgkin 's disease Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Hodgkin 's disease Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
</DOC>